Article
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Oncotarget - 7 Feb 2017
Lyberg Katarina, Ali Hani Abdulkadir, Grootens Jennine, Kjellander Matilda, Tirfing Malin, Arock Michel, Hägglund Hans, Nilsson Gunnar, Ungerstedt Johanna
Abstract excerpt
Systemic mastocytosis (SM) is a clonal bone marrow disorder, where therapeutical options are limited. Over 90% of the patients carry the D816V point mutation in the KIT receptor that renders this receptor constitutively active. We assessed the sensitivity of primary mast cells (MC) and mast cell lines HMC1.2 (D816V mutated), ROSA (KIT WT) and ROSA (KIT D816V) cells to histone deacetylase inhibitor (HDACi)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.